Calcineurin Inhibitors and Their Black Box Warnings in Pediatric AD

Panelists discuss how calcineurin inhibitors play a valuable role in managing pediatric atopic dermatitis (AD), especially for sensitive skin areas where corticosteroids may not be suitable. These treatments help reduce inflammation and itching without causing skin thinning. However, the presence of black box warnings has led to caregiver hesitation and occasional underuse.

Panelists explain that the warnings were based on limited systemic data rather than pediatric topical studies. In practice, these medications are generally well tolerated and safe when used appropriately under medical supervision. They can be particularly helpful for treating areas such as the face, neck, and skin folds.

Encouraging open dialogue between families and health care providers helps address fears and ensures treatments are used correctly. Education about risks versus benefits allows parents to make informed decisions and maintain confidence in their child’s care plan.